In this first of a 6-episode series on Emergency Use Authorization (EUA) in COVID-19, an expert explains the differences between EUA and full approval, how long EUAs last, and how new clinical trial evidence supports and changes an EUA. The discussion concludes with an overview of safety and management of potential adverse events. Claim your credit at pce.is/COV19.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox. This activity is available for CE/CME credit.
In this first of a 6-episode series on Emergency Use Authorization (EUA) in COVID-19, an expert explains the differences between EUA and full approval, how long EUAs last, and how new clinical trial evidence supports and changes an EUA. The discussion concludes with an overview of safety and management of potential adverse events. Claim your credit at pce.is/COV19.